Terms: = Leukemia AND TSC1, KIAA0243, 7248, ENSG00000165699, TSC, MGC86987, LAM, hamartin AND Prognosis
9 results:
1. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
Largeaud L; Cornillet-Lefebvre P; Hamel JF; Dumas PY; Prade N; Dufrechou S; Plenecassagnes J; Luquet I; Blanchet O; Banos A; Béné MC; Bernard M; Bertoli S; Bonmati C; Fornecker LM; Guièze R; Haddaoui L; Hunault M; Ianotto JC; Jourdan E; Ojeda M; Peterlin P; Vey N; Zerazhi H; Yosr H; Mineur A; Cahn JY; Ifrah N; Récher C; Pigneux A; Delabesse E;
Leukemia; 2021 May; 35(5):1291-1300. PubMed ID: 32943750
[TBL] [Abstract] [Full Text] [Related]
2. lam-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract] [Full Text] [Related]
3. [Leukaemia cutis during acute aleukaemic myeloid leukaemia in a two-month-old infant].
Plantin P; Firmin D; Kupfer-Bessaguet I; Staroz F; Blondin G; Le Moigne P; Berthou C
Ann Dermatol Venereol; 2008 Apr; 135(4):304-6. PubMed ID: 18420079
[TBL] [Abstract] [Full Text] [Related]
4. Identification of tsc-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD.
Lu Y; Kitaura J; Oki T; Komeno Y; Ozaki K; Kiyono M; Kumagai H; Nakajima H; Nosaka T; Aburatani H; Kitamura T
Leukemia; 2007 Nov; 21(11):2246-57. PubMed ID: 17690703
[TBL] [Abstract] [Full Text] [Related]
5. Expression of adhesion molecules in 113 patients with B-cell chronic lymphocytic leukemia: relationship with clinico-prognostic features.
Domingo A; González-Barca E; Castellsagué X; Fernandez-Sevilla A; Grañena A; Crespo N; Ferrán C
Leuk Res; 1997 Jan; 21(1):67-73. PubMed ID: 9029188
[TBL] [Abstract] [Full Text] [Related]
6. Timed sequential chemotherapy for advanced acute myeloid leukemia.
Archimbaud E; Leblond V; Fenaux P; Dombret H; Cordonnier C; Dreyfus F; Cony-Makhoul P; Tilly H; Troussard X; Auzanneau G; Thomas X; Ffrench M; Marie JP
Hematol Cell Ther; 1996 Apr; 38(2):161-7. PubMed ID: 8931997
[TBL] [Abstract] [Full Text] [Related]
7. [Contribution of immunotyping in the diagnosis and in the prognosis of acute leukemia].
Merle-Béral H; Boucheix C
Rev Prat; 1996 Jan; 46(1):30-6. PubMed ID: 8596888
[TBL] [Abstract] [Full Text] [Related]
8. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Archimbaud E; Thomas X; Leblond V; Michallet M; Fenaux P; Cordonnier C; Dreyfus F; Troussard X; Jaubert J; Travade P
J Clin Oncol; 1995 Jan; 13(1):11-8. PubMed ID: 7799010
[TBL] [Abstract] [Full Text] [Related]
9. [prognosis of hematopoietic dysplasia (author's transl)].
Dresch C; Faille A; Glogowski A; Najean Y
Nouv Rev Fr Hematol Blood Cells; 1977; 18(2):401-13. PubMed ID: 917832
[TBL] [Abstract] [Full Text] [Related]
